69 related articles for article (PubMed ID: 38693705)
1. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
[TBL] [Abstract][Full Text] [Related]
2. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
Wu Y; Hu L; Zhang S; Zhang H
Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
[No Abstract] [Full Text] [Related]
3. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study.
Guan S; Sun J; Wang Y; Han S; Chen C; Yue D; Huang Y; Ren K; Wang J; Wang J; Zhao L
Cancer Immunol Immunother; 2024 May; 73(7):120. PubMed ID: 38713243
[TBL] [Abstract][Full Text] [Related]
4. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study.
Li J; Lu S; Tian Y; Jiang L; Li L; Xie SH; Li Q
Radiother Oncol; 2024 Jul; 196():110316. PubMed ID: 38679201
[TBL] [Abstract][Full Text] [Related]
6. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
[TBL] [Abstract][Full Text] [Related]
7. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Waser NA; Quintana M; Schweikert B; Chaft JE; Berry L; Adam A; Vo L; Penrod JR; Fiore J; Berry DA; Goring S
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38521542
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis.
Dong HJ; Yang CY
Clin Respir J; 2024 May; 18(5):e13756. PubMed ID: 38725310
[TBL] [Abstract][Full Text] [Related]
9. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
Hu M; Li X; Lin H; Lu B; Wang Q; Tong L; Li H; Che N; Hung S; Han Y; Shi K; Li C; Zhang H; Liu Z; Zhang T
Int J Surg; 2024 Apr; 110(4):2275-2287. PubMed ID: 38265431
[TBL] [Abstract][Full Text] [Related]
10. Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer.
Mathey-Andrews C; McCarthy M; Potter AL; Beqari J; Wightman SC; Liou D; Raman V; Jeffrey Yang CF
J Thorac Cardiovasc Surg; 2023 Aug; 166(2):347-355.e2. PubMed ID: 36653251
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract][Full Text] [Related]
12. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis.
Ye L; Liu Y; Xiang X; Wang Z; Peng W; Wei X; Zhang S; Xue Q; Zhou Q
Heliyon; 2024 Jun; 10(11):e31549. PubMed ID: 38828349
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia.
Parera Roig M; Colomé DC; Colomer GB; Sardo EG; Tournour MA; Fernández SG; Ominetti AI; Juvanteny EP; Polo JLM; Jobal DB; Espejo-Herrera N
Curr Oncol; 2024 Apr; 31(4):2145-2157. PubMed ID: 38668062
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma.
Wu E; Reznicek J; Yeldandi AV; Patel JD; Odell DD
Clin Lung Cancer; 2024 Jun; 25(4):376-379. PubMed ID: 38462414
[No Abstract] [Full Text] [Related]
16. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
Zhang C; Sun YX; Yi DC; Jiang BY; Yan LX; Liu ZD; Peng LS; Zhang WJ; Sun H; Chen ZY; Wang DH; Peng D; Chen SA; Li SQ; Zhang Z; Tan XY; Yang J; Zhao ZY; Zhang WT; Su J; Li YS; Liao RQ; Dong S; Xu CR; Zhou Q; Yang XN; Wu YL; Zhang ZM; Zhong WZ
Cell Rep Med; 2024 Jun; ():101615. PubMed ID: 38897205
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study.
Tsuboi M; Murakami H; Harada H; Sobue T; Kato T; Atagi S; Tokito T; Mio T; Adachi H; Kozuki T; Sone T; Seike M; Toyooka S; Kitagawa H; Koto R; Yamazaki S; Horinouchi H
Thorac Cancer; 2024 May; ():. PubMed ID: 38812106
[TBL] [Abstract][Full Text] [Related]
18. Effective neoadjuvant immunotherapy and chemotherapy in stage IIIA adenosquamous carcinoma of the lung with a complete response and surgical success: A case report.
Song C; Nie Y; Liu T; Peng X; Liu J; Zhou Z; Huang Y
Oncol Lett; 2024 Jul; 28(1):314. PubMed ID: 38807664
[TBL] [Abstract][Full Text] [Related]
19. Combination of chemotherapy and immunotherapy may overcome the resistance to immunotherapy alone in pulmonary lymphoepithelial carcinoma.
Hung HY; Lai WA; Chuang CH; Yang CJ
Kaohsiung J Med Sci; 2024 Jun; 40(6):601-602. PubMed ID: 38590264
[No Abstract] [Full Text] [Related]
20. The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
Dickhoff C; Heineman DJ; van Dorp M; Senan S; Bahce I
J Thorac Oncol; 2024 Jun; 19(6):862-865. PubMed ID: 38849166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
